Previous Close | 2.5460 |
Open | 2.5640 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's Range | 2.5640 - 2.6740 |
52 Week Range | 2.4700 - 7.0340 |
Volume | |
Avg. Volume | 9,135 |
Market Cap | 432.3M |
Beta (5Y Monthly) | 0.99 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2400 |
Earnings Date | Nov 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V (S4V), the world’s most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Va
As the French market navigates through a period of heightened caution due to escalating Middle East tensions and broader European economic concerns, the CAC 40 Index has experienced a notable decline. In this environment, identifying high-growth tech stocks in France requires an understanding of companies that can demonstrate resilience and adaptability amidst geopolitical uncertainties and shifting economic landscapes.